This is a type of heart failure where the heart muscle doesn't relax properly during the filling phase (diastole). This makes it harder for the heart to fill up with blood, leading to heart failure symptoms.
Every report comes from a Lived member, sent anonymously.
Have you tried Jardiance (Empagliflozin) for Diastolic Heart Failure?
Diastolic heart failure, now usually called heart failure with preserved ejection fraction (HFpEF), is a form of heart failure in which the heart's main pumping chamber, the left ventricle, has become too stiff to relax and fill properly between beats. The heart still squeezes out a normal share of the blood it holds, but because it fills less easily, pressure backs up into the lungs and veins, and the heart cannot keep up when the body needs more blood flow. The result is the familiar picture of heart failure: shortness of breath, especially with exertion such as climbing stairs, tiredness, a reduced ability to exercise, and swelling of the ankles, legs or belly from fluid buildup. Heart failure does not mean the heart has stopped or is about to stop. It is a long-term condition that needs ongoing care, and it makes up a growing share of all heart failure, particularly in older adults and in women.
HFpEF usually develops from years of strain on the heart rather than from a single event. Long-standing high blood pressure is the main cause: the heart muscle thickens to cope with the extra workload, and thicker muscle is stiffer. Obesity and diabetes also stiffen the heart and are major contributors, and aging itself makes heart tissue less flexible. Many people with HFpEF have several of these conditions at once, along with others such as chronic kidney disease, sleep apnea, anemia or atrial fibrillation (a common irregular heart rhythm). These can contribute to the condition and also make symptoms worse. Women are more likely than men to develop this type of heart failure. Having these risk factors raises the likelihood of HFpEF but does not mean it will develop, and treating them is a central part of care.
No single test confirms HFpEF, which is one reason it can be missed. A clinician starts with symptoms, an examination for signs of fluid such as leg swelling or crackles in the lungs, and a review of related conditions such as blood pressure, weight and diabetes. An electrocardiogram (ECG), a recording of the heart's electrical activity, often comes first. An echocardiogram, an ultrasound of the heart, is the key test. It measures the ejection fraction, the percentage of blood in the left ventricle that is pumped out with each beat. An ejection fraction of 50% or more is called preserved. One of 40% or less is called reduced, a different form of heart failure with different treatment, and 41% to 49% falls in between. Because a normal ejection fraction on its own does not show that anything is wrong, the echocardiogram also looks for signs that the ventricle is stiff and that pressure inside the heart is raised. Blood tests for BNP (B-type natriuretic peptide), a hormone the heart releases when it is under strain, support the diagnosis, although a normal level does not rule HFpEF out. When the picture is unclear, an exercise or stress test, or cardiac catheterization to measure pressures inside the heart directly, may help. Clinicians also look for conditions that can mimic HFpEF, including lung disease, heart valve problems and less common causes of a stiff heart such as amyloidosis.
Treatment aims to relieve symptoms, keep people out of the hospital and manage the conditions driving the disease. Diuretics (water pills) remove excess fluid and are usually the quickest way to ease breathlessness and swelling. The dose often needs adjusting over time, because too much can cause dizziness, low blood pressure or strain on the kidneys. Two kinds of medicine now form the base of long-term treatment when they are suitable. SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors), such as empagliflozin (Jardiance) and dapagliflozin (Farxiga), are tablets first developed for diabetes that also lower the risk of being hospitalized for heart failure, including in people who do not have diabetes. Finerenone (Kerendia) blocks the effects of aldosterone, a hormone that makes the body hold on to salt and water, and is approved for heart failure with an ejection fraction of 40% or higher. It can raise blood potassium, so potassium and kidney function are checked before and during treatment. For both kinds of medicine, the main benefit seen in trials is fewer episodes of worsening heart failure and fewer hospital visits, rather than a clear gain in survival. Obesity is common in HFpEF, and for people who have it, weight loss can make a real difference. GLP-1 (glucagon-like peptide-1) medicines used for weight loss, such as semaglutide (Wegovy) and tirzepatide (Zepbound), are not specifically approved for heart failure, but in trials of people with HFpEF and obesity they improved breathlessness, walking distance and quality of life, and heart specialists now include them in HFpEF care. Digestive side effects such as nausea are common. Controlling blood pressure, treating atrial fibrillation, sleep apnea and diabetes, limiting salt and staying physically active are as much a part of treatment as any single medicine. Regular exercise, often started in a supervised cardiac rehabilitation program, can improve how much activity people can manage, although the studies so far are small. Proven treatments for HFpEF are fewer and newer than those for heart failure with reduced ejection fraction, so a treatment plan may look different from that of someone with the other type.
HFpEF is a long-term condition, and treatment usually continues for life. Treatment can help people live more actively with fewer symptoms, but the course varies. Symptoms may stay stable for long stretches and then flare, often set off by an infection, a high-salt meal, missed medicines, poorly controlled blood pressure or a new irregular heart rhythm. Hospital stays for worsening heart failure are common. On average the outlook is somewhat better than for heart failure with reduced ejection fraction, but HFpEF remains a serious condition. Daily routines matter. Many people weigh themselves every morning, before eating and after using the bathroom, because a quick gain often means fluid is building up before breathlessness becomes obvious. Limiting salt, and sometimes fluids, helps keep swelling down. Common pain relievers such as ibuprofen (Advil, Motrin) and naproxen (Aleve) can make heart failure worse, so it is worth checking with a clinician or pharmacist before starting any new medicine or supplement. Follow-up visits usually happen at least every three to six months, often with blood tests to check kidney function and potassium levels. Living with heart failure can bring anxiety or low mood, and counseling and support groups can help. For advanced illness, palliative care focused on comfort and symptom relief can improve quality of life alongside heart treatment.
See a clinician if breathlessness with ordinary activity, tiredness that limits what you can do, or swelling in your ankles or legs develops, especially if you have high blood pressure, diabetes or obesity. If you already have HFpEF, contact your care team if your weight rises by more than 2 to 3 pounds in a day or 5 pounds in a week, if swelling increases, or if a medicine seems to be causing side effects such as dizziness. Call your care team right away if you become short of breath when lying down or wake at night needing to sit up to breathe, if you can manage noticeably less everyday activity than usual, or if you cough up frothy or pink-tinged phlegm. Call 911 if you have severe difficulty breathing (gasping or unable to get words out), lips or skin that turn blue or gray, severe chest pain, fainting, or a fast, irregular heartbeat along with other symptoms.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Diastolic Heart Failure is like, what's helped you, or ask the community a question.